Connect Biopharma Holdings Ltd (CNTB) Form 8-K — Aug 12, 2026
Connect Biopharma reported a second quarter 2026 net loss of $17.3 million, or $0.27 per share, versus a $12.9 million, or $0.23 per share, loss in the year-ago quarter, as rademikibart development costs pushed R&D expense to $16.3 million from $8.8 million. The company completed enrollment in its Phase 2 Seabreeze STAT asthma and COPD studies (160 and 159 participants, respectively) and expects topline results from both trials in September 2026, with a planned FDA meeting afterward on a potential Phase 3 program. A 40-participant open-label Seabreeze STAT IV study was initiated in August 2026.
Key figures
- Revenue
- 2768000
- Guidance
- Cash, cash equivalents and short-term investments expected to be sufficient to meet anticipated cash requirements for a period of at least one year from the August 12, 2026 release date.
- Total Assets
- 43472000
- Cash Position
- 31486000
- Ga expense q2
- 4099000
- Rd expense q2
- 16273000
- Cash dec 31 2025
- 44342000
- Shareholders equity
- 26861000
- Iv study participants
- 40
- Topline data expected
- September 2026
- Copd study participants
- 159
- Ga expense q2 prior year
- 4699000
- Rd expense q2 prior year
- 8773000
- Asthma study participants
- 160
- License revenue six months
- 2937000
- License revenue q2 prior year
- 48000
- Simcere remaining milestones usd
- approximately $99 million
- Weighted avg shares q2 thousands
- 62884
Price after filing
Close on the filing date to close N calendar days later (from $2.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.